UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S198-S199

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study

Journal of hepatology, 2017, Vol.66 (1), p.S521-S522

2017

Link zum Volltext

Verfügbarkeit prüfen

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

Journal of hepatology, 2017, Vol.66 (1), p.S668-S669

2017

Link zum Volltext

Verfügbarkeit prüfen

I-26 Immunology of HBV infection

International journal of infectious diseases, 2008, Vol.12, p.S9-S10

Vierling, J.M

2008

Link zum Volltext

Verfügbarkeit prüfen

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S197-S197

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Journal of hepatology, 2017, Vol.66 (1), p.S85-S85

2017

Link zum Volltext

Verfügbarkeit prüfen

P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection

Journal of hepatology, 2015-04, Vol.62, p.S618-S618

2015

Link zum Volltext

Verfügbarkeit prüfen

LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study

Journal of hepatology, 2015-04, Vol.62, p.S261-S262

2015

Link zum Volltext

Verfügbarkeit prüfen

Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study

Journal of hepatology, 2016, Vol.64 (2), p.S768-S769

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

Journal of hepatology, 2017, Vol.66 (1), p.S315-S316

2017

Link zum Volltext

Verfügbarkeit prüfen

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

Journal of hepatology, 2010, Vol.52, p.S470-S471

2010

Link zum Volltext

Verfügbarkeit prüfen

248 FASTING AMMONIA (NH3) AS A PREDICTOR OF HEPATIC ENCEPHALOPATHY (HE) EVENTS

Journal of hepatology, 2013-04, Vol.58, p.S106-S106

2013

Link zum Volltext

Verfügbarkeit prüfen

205 LONG TERM OUTCOMES OF PORTOPULMONARY HYPERTENSION (POPH) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)

Journal of hepatology, 2013-04, Vol.58, p.S89-S90

2013

Link zum Volltext

Verfügbarkeit prüfen

O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

Journal of hepatology, 2014-04, Vol.60 (1), p.S14-S14

2014

Link zum Volltext

Verfügbarkeit prüfen

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S5-S5

2014

Link zum Volltext

Verfügbarkeit prüfen

LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir

Journal of hepatology, 2015-04, Vol.62, p.S271-S272

2015

Link zum Volltext

Verfügbarkeit prüfen

627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

Journal of hepatology, 2009, Vol.50, p.S230-S231

2009

Link zum Volltext

Verfügbarkeit prüfen

P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS

Journal of hepatology, 2014-04, Vol.60 (1), p.S457-S458

2014

Link zum Volltext

Verfügbarkeit prüfen

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

Journal of hepatology, 2013-04, Vol.58, p.S30-S30

2013

Link zum Volltext

Verfügbarkeit prüfen

13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION

Journal of hepatology, 2013-04, Vol.58, p.S6-S6

2013

Link zum Volltext

Verfügbarkeit prüfen

1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS

Journal of hepatology, 2013-04, Vol.58, p.S576-S577

2013

Link zum Volltext

Verfügbarkeit prüfen

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S184-S184

2011

Link zum Volltext

Verfügbarkeit prüfen

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S183-S183

2011

Link zum Volltext

Verfügbarkeit prüfen

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

Journal of hepatology, 2011-03, Vol.54, p.S4-S4

2011

Link zum Volltext

Verfügbarkeit prüfen

1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL

Journal of hepatology, 2011-03, Vol.54, p.S538-S538

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Gastroenterology And Hepatology
(27)
Science & Technology
(9)
Life Sciences & Biomedicine
(7)
Biological And Medical Sciences
(4)
Humans
(3)
Adult
(2)
Animals
(2)
Chemistry
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Gene
(2)
Genes
(2)
Genetics & Heredity
(2)
Glycine Max
(2)
Heterodera Glycines
(2)
Liver - Metabolism
(2)
Medical Sciences
(2)
Middle Aged
(2)
Physical Sciences
(2)
Plant Sciences
(2)
Surgery
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

I-26 Immunology of HBV infection

481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

P0769 : Efficacy of an eight-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, noncirrhotic HCV genotype 1B infection

LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study

Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study

Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

248 FASTING AMMONIA (NH3) AS A PREDICTOR OF HEPATIC ENCEPHALOPATHY (HE) EVENTS

205 LONG TERM OUTCOMES OF PORTOPULMONARY HYPERTENSION (POPH) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)

O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

LP17 : Novel approach for the prevention of recurrent hepatitis C in liver transplant recipients: Preliminary results from ongoing phase III trial with civacir

627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES

P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSIS

66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION

1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES

1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL

Suchergebnisse filtern